Imunon, Inc. (NASDAQ:IMNN – Free Report) – HC Wainwright raised their Q3 2026 earnings estimates for shares of Imunon in a report issued on Thursday, August 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.57) per share for the quarter, up from their prior estimate of ($0.84). The consensus estimate for Imunon’s current full-year earnings is ($2.63) per share. HC Wainwright also issued estimates for Imunon’s Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.06) EPS, FY2028 earnings at ($1.05) EPS, FY2029 earnings at ($0.73) EPS and FY2030 earnings at ($0.53) EPS.
Imunon (NASDAQ:IMNN – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.33.
Get Our Latest Analysis on IMNN
Imunon Stock Performance
NASDAQ:IMNN opened at $1.60 on Monday. The firm has a market capitalization of $8.98 million, a PE ratio of -0.42 and a beta of 1.97. The business’s fifty day moving average price is $1.78 and its 200 day moving average price is $2.50. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.82 and a quick ratio of 1.82. Imunon has a 12 month low of $1.47 and a 12 month high of $6.96.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Imunon stock. Armistice Capital LLC purchased a new stake in Imunon, Inc. (NASDAQ:IMNN – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 266,886 shares of the company’s stock, valued at approximately $1,017,000. Armistice Capital LLC owned about 8.69% of Imunon at the end of the most recent reporting period. 4.47% of the stock is currently owned by hedge funds and other institutional investors.
Imunon Company Profile
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
Featured Articles
- Five stocks we like better than Imunon
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
